In the latest close session, Novo Nordisk (NVO) was down 2.14% at $40.29. This move lagged the S&P 500’s daily loss of 0.04%. Meanwhile, the Dow experienced a drop of 0.57%, and the technology-dominated Nasdaq saw an increase of 0.04%.

Shares of the drugmaker witnessed a gain of 12.03% over the previous month, beating the performance of the Medical sector with its loss of 0.72%, and underperforming the S&P 500’s gain of 12.24%.

Analysts and investors alike will be keeping a close eye on the performance of Novo Nordisk in its upcoming earnings disclosure. The company’s earnings report is set to go public on May 6, 2026. The company’s upcoming EPS is projected at $0.87, signifying a 5.43% drop compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.13 billion, up 1.08% from the year-ago period.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.34 per share and a revenue of $45.44 billion, representing changes of -15.66% and -2.87%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for Novo Nordisk. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we’ve crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.6% decrease. Novo Nordisk is holding a Zacks Rank of #3 (Hold) right now.

Looking at its valuation, Novo Nordisk is holding a Forward P/E ratio of 12.34. For comparison, its industry has an average Forward P/E of 13.88, which means Novo Nordisk is trading at a discount to the group.

Also, we should mention that NVO has a PEG ratio of 9.8. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company’s expected earnings growth rate. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 2.23.